德克拉伐替尼 (BMS-986165)

德克拉伐替尼 (BMS-986165)（CAS 1609392-27-9）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的记载用途

Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is not recommended for use in combination with other potent immunosuppressants. It is also indicated for the treatment of psoriatic arthritis in adults.Deucravacitinib is a small molecule inhibitor of tyrosine kinase 2 that is used in the treatment of moderate-to-severe plaque psoriasis. Deucravacitinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy but has not been linked instances of clinically apparent acute liver injury.

同义词与商品名

Deucravacitinib; 1609392-27-9; BMS-986165; Sotyktu; N0A21N6RAU; RefChem:58358; Tyk2-IN-4; BMS986165; Deucravacitinib [USAN]; MFCD31715455; Deucravacitinib (BMS-986165); Tyk2-IN-4(BMS986165); bms 986165; Sotyktu (TN); Deucravacitinib [MI]; UNII-N0A21N6RAU

已收录的法规名录

GHS notification summary	33.3% (1 / 3)

GHS 危害分类

GHS notification summary	33.3% (1 / 3)
Reported hazard statements	H361 (33.3%), H372 (66.7%)

This chemical does not meet GHS hazard criteria for 33.3% (1 of 3) of reports.

H361 (33.3%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

公开数据库对它的描述

Deucravacitinib (BMS-986165) · CAS 1609392-27-9 · C20H22N8O3. UNII N0A21N6RAU.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。